Objective:To summarize the clinical presentations of patients complicated with type1 diabetes mellitus(T1DM)following immune checkpoint inhibitor therapy(ICIT1D)for improving understanding of this rare complication.Methods:Observation and analysis were conducted in one case of ICIT1D regarding the clinical data,laboratory findings,and follow-up outcomes,with relevant literatures reviewed.Results:T1DM for the patient was presumably induced by the programmed death receptor-1(PD-1)inhibitor karelizumab.The disease exhibited a rapid onset,with diabetic ketoacidosis(DKA)as the initial presentation.Laboratory evaluations revealed low insulin C-peptide levels and negative islet autoantibodies.The patient's condition was improved following interventions including rehydration,glucose-lowering,and acid-correcting therapies.Conclusion:Patients without history of diabetes that occurs soon after immune checkpoint inhibitor therapy,particularly presenting DKA at first,should be alerted to be potential ICIT1D.
关键词
免疫检查点抑制剂/1型糖尿病/糖尿病酮症酸中毒/程序性死亡受体1/卡瑞利珠单抗
Key words
immune checkpoint inhibitor/type 1 diabetes mellitus/diabetic ketoacidosis/programmed death ligand 1/camrelizumab
维普
万方数据